FDA Weighs COVID Vaccine Composition
FDA advisers to discuss COVID vaccine composition for 2026-2027, potentially impacting vaccine makers' stocks. Decision may affect vaccine efficacy and demand.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.